Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIVE-STAR: Finerenone on Vascular Stiffness in T2D and CKD
NCT05887817Phase 4Active, not recruiting
- Sponsor
- Saga University
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone with Placebo (2 arms). Primary endpoint: Cardio-Ankle Vascular Index at 24 weeks. Started Sep 2023; status: active, not recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05887817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887817.